Output details

Valproate and Bone Loss: iTRAQ Proteomics Show that Valproate Reduces Collagens and Osteonectin in SMA Cells

Valproate is a drug that was introduced more than 40 years ago and is commonly used to treat epilepsy, mood disorders, and has been considered for treatment of spinal muscular atrophy (SMA). Its long-term side effects can include bone loss, although this mechanism was unclear. This work showed for the first time that valproate reduced the amount of two key bone proteins (collagen I and osteonectin); thus suggesting a possible molecular mechanism for bone loss following long-term exposure to valproate. This work was mentioned in various online press releases (e.g. http://www.sciencedaily.com/releases/2010/08/100804122713.htm, http://www.news-medical.net/news/20100805/Long-term-exposure-to-valproate-leads-to-bone-loss-Study.aspx, http://www.medscape.com/viewarticle/726643).